Indian Pharma Stocks Plunge Amid US Tariff Threat

Q: What are the potential tariffs on drug imports?

The US government is considering imposing **100% tariffs** on certain imported drugs.

Q: How did the market react to the tariff news?

The Nifty Pharma index dropped over **2%**, with major pharmaceutical stocks falling up to **3%**.

Original: Sun Pharma, Aurobindo, Biocon Fall As US Mulls 100% Tariffs On Drug Imports

News 18•Apr 2, 20262 min

In a Nutshell

Shares of Indian pharmaceutical companies, including Sun Pharmaceuticals, Aurobindo Pharma, and Biocon, fell sharply as the US government considers imposing 100% tariffs on certain imported drugs. The Nifty Pharma index dropped over 2%, reflecting market panic over potential new trade measures targeting offshore manufacturers.

Key Points

01Indian pharma stocks fell due to US tariff threats.
02Sun Pharma, Aurobindo, and Biocon experienced declines of up to 3%.
03The Nifty Pharma index dropped over 2% before recovering.
04Tariffs are linked to a national security investigation under Section 232.
05Previous warnings from former President Donald Trump indicated potential tariffs on imported drugs.

In-Article Ad

Full Summary

On Thursday, shares of Indian pharmaceutical companies were significantly impacted as reports emerged that the Trump administration is considering 100% tariffs on certain imported medicines. Major players like Sun Pharmaceuticals, Aurobindo Pharma, and Biocon saw their stocks decline by as much as 3% during intraday trading. The Nifty Pharma index fell over 2%, reaching a low of 21,149 before partially recovering to around 21,642. The proposed tariffs are reportedly based on a national security investigation initiated in April under Section 232 of the Trade Expansion Act of 1962. This move follows earlier warnings from Donald Trump about imposing tariffs on branded or patented drugs unless companies establish manufacturing operations in the United States. Notably, these tariffs would not be affected by a recent Supreme Court ruling that struck down emergency tariffs on imports.

Key Figures

100%

Proposed tariff rate on certain imported drugs

2%

Drop in the Nifty Pharma index

3%

Maximum intraday decline in shares of major pharma companies

In-Article Ad

Why It Matters

The potential tariffs could lead to increased drug prices in the US, affecting affordability for consumers. Indian pharmaceutical companies may face significant operational challenges if they do not establish manufacturing in the US.

Who is affected

Consumers in the US, Indian pharmaceutical companies, and their shareholders.

What to know

Investors should monitor the developments regarding US tariffs and consider the implications for their investments in Indian pharma stocks.

FAQ

The US government is considering imposing 100% tariffs on certain imported drugs.

The Nifty Pharma index dropped over 2%, with major pharmaceutical stocks falling up to 3%.

Read the original article →